CAI:PHAR's ROA % is ranked better than 67.8% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs CAI:PHAR: 6.06
Egyptian International Pharmaceutical Investments (CAI:PHAR) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Egyptian International Pharmaceutical Investments ROA % Related Terms
Egyptian International Pharmaceutical Investments ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments ROA % Chart
Egyptian International Pharmaceutical Investments Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments ROA % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a ROA % of 6.34% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 51% below median its historical median of 12.92. Over the past decade, Egyptian International Pharmaceutical Investments' ROA % has ranged from 6.06 to 22.74. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #323 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Egyptian International Pharmaceutical Investments' ROA % too high?
Egyptian International Pharmaceutical Investments' current ROA % of 6.34% is 51% below median its 10-year median of 12.92. Over the past 10 years, this metric has ranged from a low of 6.06 to a high of 22.74. The Drug Manufacturers industry median ROA % is 2.69. Egyptian International Pharmaceutical Investments' value of 6.34% is 135.7% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #323 out of 1003 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #323 out of 1003 companies for ROA %. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median ROA % is 2.69. Egyptian International Pharmaceutical Investments' value of 6.34% is 135.7% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own ROA % has ranged from 6.06 to 22.74 over the past decade. While the company's 10-year median is 12.92 vs. the industry median of 2.69, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current ROA % of 6.34% is 135.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current ROA % is 6.34%, which is 51% below median its own 10-year median of 12.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.67, compared to a current price of E£84.69 — trading 41.9% above its estimated fair value. The current ROA % is 6.34%, which is 51% below median its 10-year median of 12.92 and 135.7% above the Drug Manufacturers industry median of 2.69. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current ROA % is 6.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£84.69 is trading 41.9% above its estimated GF Value™ of E£59.67.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
ROA %: 6.34% (51% below median its 10-year median of 12.92)
GF Value™: E£59.67 vs. price of E£84.69 (41.9% above fair value)
Industry Position: 135.7% above the Drug Manufacturers median (#323 of 1003)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score
Get the complete analysis for CAI:PHAR
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
